ClinicalTrials.gg
RecruitingNCT07614191Updated Jun 2, 2026

A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases

An Early Phase 1 interventional study of GT801 Injection in Moderate to Severe Refractory Autoimmune Diseases, sponsored by Vivacta Biotechnology (Shanghai) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Vivacta Biotechnology (Shanghai) Co., Ltd. · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies in Autoimmune Diseases with a site in China — 72 open to participants now, 78 under way, 7 of them phase 3. Autoimmune Diseases · China.

Planned enrollment
62nd of 113
22 · median 30
Started
2026
with 16 others
Phase 1
57 of 125
40 open now
Primary completion
2031-12
later than 77 of 77 live
Registered
118th of 125
by date

Among the 125 studies in Autoimmune Diseases with a site in China, this one is the 62nd largest by planned enrollment of the 113 interventional ones that give a count, is one of 17 that started in 2026, is one of 57 in phase 1, reaches primary completion later than 77 of the 77 other live ones, and was the 118th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

72 of the 125 studies in Autoimmune Diseases with a site in China are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Autoimmune Diseases with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, single-arm, dose-escalation and dose-expansion clinical trial designed to evaluate the safety, efficacy and cellular pharmacokinetics of GT801 injection in patients with moderate to severe refractory autoimmune diseases.

03

Conditions studied

  • Moderate to Severe Refractory Autoimmune Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.The participant or their legal representative voluntarily signs a written form and is willing and able to comply with the study procedures.
  • 2. Aged 18 to 65 years old (inclusive) at the time of signing the informed consent, regardless of gender.
  • 3.subjects should be diagnosed with recurrent or diseases, including but not limited to systemic lupus erythematosus (SLE), lupus nephritis (LN), membranous nephropathy (MN), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA-Associated Vasculitis (AAV), Sjogren's Syndrome.
  • 4.Organ function meets the corresponding criteria.
  • 5.Women of must have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result at screening and agree to avoid breastfeeding during study participation until at least 1 year after GT801 injection or until GT801 cells are no longer detectable by two consecutive flow cytometry tests, whichever is later.

Exclusion criteria

Exclusion Criteria:

  • 1. History of severe reactions or allergies.
  • 2. to or hypersensitivity reactions to any component of the product.
  • 3. History of the following cardiac diseases:
  • a. (NYHA) Class III or IV congestive heart failure.
  • b. Myocardial infarction or coronary artery bypass grafting within 6 months prior to screening.
  • c. History of ventricular arrhythmia or unexplained syncope not caused by vasovagal response or dehydration; or interval (QTc) > 480 ms at screening; history of severe non-ischemic cardiomyopathy.
  • 4. History of any active or malignant tumor within 5 years prior to screening, except for the following conditions: early-stage tumors treated with curative intent (carcinoma in situ or Stage I tumors, non-ulcerative primary melanoma with depth \< 1 mm and no lymph node involvement), basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, or ductal carcinoma in situ of the breast that has undergone potentially curative treatment.
  • 5. Any other known diseases besides the study disease.
  • 6. Long-term use of anticoagulant drugs that affect coagulation function.
  • 7. Clinically significant bleeding symptoms or confirmed bleeding tendency within 6 months prior to screening (e.g., gastrointestinal bleeding, hemorrhagic gastric ulcer, etc.); hereditary or acquired bleeding and thrombotic tendencies (e.g., hemophilia, coagulation disorders, hypersplenism, etc.); arterial or venous thrombotic events within 6 months prior to screening (e.g., cerebrovascular diseases including cerebral hemorrhage and cerebral infarction, deep vein thrombosis, and/or pulmonary embolism).
  • 8. Subjects with active virus infection including (HIV), virus (HBV), virus (HCV), cytomegalovirus (CMV), syphilis and tuberculosis etc.
  • 9. Receipt of other investigational drugs within 4 weeks prior to signing the form (ICF); or the interval between the ICF signing date and the last dose of the previous clinical trial participation is still within 5 half-lives of the drug, whichever is longer.
  • 10. Receipt of plasma exchange therapy or immunoadsorption therapy within 4 weeks prior to investigational product administration.
  • 11. Prior treatment with B-cell targeted therapies within 3 months prior to study drug administration (the investigator may make appropriate adjustments according to the participant's condition), including but not limited to rituximab, belimumab, telitacicept, etc.
  • 12. Receipt of biologic therapy such as anti-TNF-α antibodies within 12 weeks prior to investigational product administration.
  • 13. Use of tacrolimus, cyclosporine, azathioprine, mycophenolate mofetil, mycophenolic acid, methotrexate, etc., within 2 weeks prior to investigational product administration.
  • 14. Receipt of neonatal Fc receptor (FcRn) antagonist therapy (e.g., efgartigimod, etc.) within 3 weeks prior to investigational product administration.
  • 15. Receipt of complement inhibition therapy (e.g., eculizumab, etc.) within 3 weeks prior to investigational product administration.
  • 16. Vaccination with or mRNA vaccines within 8 weeks prior to enrollment; or inactivated vaccines within 4 weeks prior to enrollment.
  • 17. Major surgery within 8 weeks prior to screening, or planned surgery during the study period.
  • 18. History of organ transplantation.
  • 19. Prior receipt of chimeric antigen receptor T-cell (CAR-T) therapy targeting any antigen.
  • 20. Presence of any conditions that, in the investigator's judgment, would prevent the participant from completing the entire trial, confound trial results, or make trial participation not in the participant's best interest.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    GT801 Injection treatment group

    GT801 Injection

    Biological: GT801 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants experiencing dose limiting toxicity

    The proportion of participants with dose-limiting toxicity (DLT) occurring within 28 days after infusion

    Time frame: 28 days

  2. Adverse Events (AEs) occurring after infusion and their proportions

    Adverse Events (AEs) occurring after infusion and their proportions

    Time frame: 3 months

Secondary outcomes

  1. Efficacy outcomes for Systemic Lupus Erythematosus (SLE)

    SLE Response index 4(SRI-4) response: Min/Max Value: Not specified; a decrease in score indicates improvment, higher scores indicate worse outcome

    Time frame: 1, 2, 3 and 6 Months post GT801 infusion

  2. Efficacy outcomes for lupus nephritis (LN)

    Renal response rate

    Time frame: 1, 2, 3 and 6 Months post GT801 infusion

  3. Efficacy outcomes for membranous nephropathy (MN)

    Renal response rate

    Time frame: 1, 2, 3 and 6 Months post GT801 infusion

  4. Efficacy outcomes for Idiopathic Inflammatory Myopathies (IIM)

    Total lmprovement Score (TlS): Min/Max Value: Not specified; an increase in score indicates improvement, higher scores indicate better outcome.

    Time frame: 1, 2, 3 and 6 Months post GT801 infusion

  5. Efficacy outcomes for Systemic Sclerosis (SSc)

    Combined Response Index in Systemic Sclerosis (CRISS): the score ranges from 0 to 1 point; a score ≥ 0.6 indicates treatment improvement, while a score \< 0.6 indicates no disease improvement.

    Time frame: 1, 2, 3 and 6 Months post GT801 infusion

  6. Efficacy Outcomes for ANCA-Associated Vasculitis (AAV)

    The proportion of subjects achieving complete remission and partial remission

    Time frame: 6 and 12 Months post GT801 infusion

  7. Efficacy Outcomes for Participants with Sjogren's Syndrome

    EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)response rates

    Time frame: 6 and 12 Months post GT801 infusion

  8. Efficacy Outcomes for Participants with Sjogren's Syndrome

    EULAR Sjögren's Syndrome Patient-Reported Index (ESSPRI)response rates

    Time frame: 6 and 12 Months post GT801 infusion

  9. Cellular Kinetics of All Participants: Time to Peak Expansion of GT801 Cells After Infusion (Tmax)

    Time to Peak Expansion (Tmax) refers to the time point at which the infused target cells proliferate to the peak quantity in the participants' bodies.

    Time frame: From infusion to 12 months

  10. Cellular Kinetics of All Participants: Expansion Peak of GT801 Cells After Infusion (Cmax)

    Expansion Peak (Cmax) refers to the maximum quantity of infused GT801 cells achieved during their proliferation in the participants' bodies.

    Time frame: From infusion to 12 months

  11. Cellular Kinetics of All Participants: Area Under the Curve (AUC) of GT801 Cells After Infusion

    Area Under the Curve (AUC) refers to the area enclosed by the curve of GT801 cell quantity change over time after infusion and the time axis.

    Time frame: From infusion to 12 months

  12. Cellular Kinetics of All Participants: Duration of Detectable Concentration of GT801 Cells After Infusion (Tlast)

    Duration of Detectable Concentration (Tlast) refers to the time period from the infusion of GT801 cells to the last time point at which the target cells can be detected in the peripheral blood or target tissues.

    Time frame: From infusion to 12 months

  13. Pharmacodynamic characteristics in participants for all participants

    Monitor serum cytokine levels after infusion

    Time frame: From infusion to 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2031, 67 months after the start.

Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 67 months is above that.

Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
May 29, 2026
StartActual
May 25, 2026
Primary completionEst.
Dec 30, 2031
CompletionEst.
Dec 30, 2031
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07614191
Lead sponsor
Vivacta Biotechnology (Shanghai) Co., Ltd.
Collaborators
RenJi Hospital
Responsible party
Sponsor
First posted
May 29, 2026
Start date
May 25, 2026
Primary completion
Dec 30, 2031 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Jun 2, 2026

Study contacts

Hong Cai
Contact
18621576622@163.com
+86 18621576622

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GT801

Start the discussion